IJMS | Free Full-Text | Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Frontiers | Molecular Network of Colorectal Cancer and Current Therapeutic Options
VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab | 2 Minute Medicine
Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database in: Journal of the National Comprehensive Cancer Network Volume 19 Issue 3 (2021)
KRAS and extended RAS molecular profiling in metastatic colorectal cancer | Colorectal Cancer
Personalized Cancer Treatment and the Myth of KRAS Wild-type Colon Tumors - Barbara L Parsons - Discovery Medicine
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text
Full article: Discovery of a novel and a rare Kristen rat sarcoma viral oncogene homolog (KRAS) gene mutation in colorectal cancer patients
KRAS Biomarker | Colorectal Cancer Alliance
Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
APMG Colon Molecular Pathways
KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study | BMJ Open
The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study - Chida - 2021 - The Oncologist - Wiley Online Library
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer | Semantic Scholar
Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer | PNAS
Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer
Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations | Journal of Proteome Research
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text
ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer: Cell Reports
The mutation distribution of KRAS/NRAS/BRAF in (A) colon cancer, (B)... | Download Scientific Diagram
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers - ScienceDirect
The Trouble With KRAS - Cancer Commons
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C | NEJM
The current understanding on the impact of KRAS on colorectal cancer - ScienceDirect
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer - The Lancet Oncology
